From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future
This article traces the evolution of API-in-capsule (AIC) technology, from its early disruption of traditional formulation through the Xcelodose® system, to its reinvention in 3P innovation’s Fill2Weight platform. The authors explore how AIC has shifted from a risky bet to a scalable solution for modern drug development. Looking ahead, they highlight the transformative role AIC…
Read MorePushing the Boundaries: Overcoming Formulation and Manufacturing Challenges (eBook w/ Pharmaceutical Technology)
Winning Strategies For Oral Dosage Form Development and Manufacturing. An eBook in partnership with Pharmaceutical Technology. Oral solid dose (OSD) formulation development must adhere to common considerations, such as project timelines, facilitating CDMO/client transparency and overcoming regulatory challenges. However, development’s difficulty often is compounded by numerous factors such as API supply constraints, challenging physiochemical properties,…
Read MoreCollaborative Innovation in CDMOs: Interview Series with Pharmaceutical Technology (5-part)
This 5-part Pharmaceutical Technology interview series with Dave Miller, Ph.D., CSO of AustinPx, explores how the role of CDMOs is evolving from transactional service providers to true co-developers. Across the series, Dave shares insights on early engagement strategies, protecting and leveraging intellectual property, and applying advanced formulation tools like KinetiSol to solve complex drug delivery challenges. Each…
Read MoreHow to Solve Complex Pediatric Dosing Challenges Using Tailored Solutions
In this article, Dave Miller, Ph.D. (CSO, AustinPx) explores why pediatric drug development demands more than simply reducing an adult dose. From palatability and swallowability to the precision required for weight-based dosing, these projects carry unique scientific, regulatory, and manufacturing hurdles. The piece highlights how mini tablets can offer the stability, flexibility, and patient compliance…
Read MoreAI Might Find the Molecule, but Delivery Decides Whether it Becomes a Medicine
In this article, AustinPx Chief Scientific Officer Dave Miller examines how the rapid expansion of AI-enabled drug discovery is reshaping the pharmaceutical pipeline. While advanced computational tools can now identify and optimize candidate molecules at unprecedented speed, many of these compounds present significant challenges once they transition from virtual design into experimental development. Issues such…
Read MoreSolving the Problem of Insolubility: The Medicine Maker Interview Series (3-part)
In this three-part interview series with The Medicine Maker, AustinPx CEO Elizabeth Hickman and CSO Dave Miller examine the growing challenge of poorly soluble drug candidates and what it means for modern drug development. As advances in AI-driven discovery, structure-based design, and in silico screening unlock increasingly complex molecules, formulation and manufacturing strategies must evolve to…
Read MoreRe-Thinking the Pipeline: Development in the Age of AI
In this article, AustinPx’s CEO, Elizabeth Hickman, examines how artificial intelligence is reshaping the front end of drug discovery and what that shift means for development. AI-driven tools are enabling researchers to design and evaluate increasingly complex molecules at unprecedented speed, expanding access to targets that were once considered undruggable. However, many of these AI-designed…
Read MoreFrom In Silico to In Vivo: Why Development Strategy Now Determines AI-Era Success
In this article, AustinPx CSO Dave Miller examines how artificial intelligence (AI) is reshaping the front end of drug discovery while exposing a growing gap between faster candidate generation and real-world developability. As AI helps researchers design increasingly complex molecules, formulation, stability, manufacturability, and scale-up challenges still determine whether those candidates can become viable medicines.…
Read MoreHow CDMOs Turn “Undruggable” Into “Developable”
AustinPx CEO Elizabeth Hickman and CSO Dave Miller examine how precision medicine, AI, and advanced discovery tools are expanding what is possible in drug development while creating new formulation and manufacturing challenges. As researchers pursue more targeted molecules, many candidates come with difficult chemistry, including poor solubility, low permeability, stability concerns, and scale-up risk. The…
Read MoreBeyond Solvents: The Future of Sustainable Amorphous Dispersion Development
AustinPx CEO Elizabeth Hickman examines why greener amorphous solid dispersion (ASD) development requires more than simply reducing solvent use. As sustainability expectations grow, she explains how cost, risk, timelines, and long-term asset value are all shaped by the complexity of the manufacturing process itself. The article explores how traditional solvent-based ASD approaches can introduce added…
Read More